Overview

• Nanomi BV, Lupin’s wholly owned subsidiary, signed a definitive agreement to buy Amsterdam-based VISUfarma from GHO Capital.
• Lupin will finance the €190 million enterprise value deal with existing cash on its balance sheet.
• VISUfarma adds established operations in Italy, the UK, Spain, Germany and France along with a portfolio of more than 60 ophthalmology brands.
• The transaction is expected to close by the end of 2025 subject to customary approvals and is projected to be accretive to growth and margins.
• VISUfarma’s 2025 revenue is estimated at about €54 million, and Centerview advised Lupin while Stifel advised GHO on the deal.